135 related articles for article (PubMed ID: 15340006)
1. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures.
Lanz TA; Fici GJ; Merchant KM
J Pharmacol Exp Ther; 2005 Jan; 312(1):399-406. PubMed ID: 15340006
[TBL] [Abstract][Full Text] [Related]
2. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
[TBL] [Abstract][Full Text] [Related]
3. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
Lanz TA; Hosley JD; Adams WJ; Merchant KM
J Pharmacol Exp Ther; 2004 Apr; 309(1):49-55. PubMed ID: 14718585
[TBL] [Abstract][Full Text] [Related]
4. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
6. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Weggen S; Eriksen JL; Das P; Sagi SA; Wang R; Pietrzik CU; Findlay KA; Smith TE; Murphy MP; Bulter T; Kang DE; Marquez-Sterling N; Golde TE; Koo EH
Nature; 2001 Nov; 414(6860):212-6. PubMed ID: 11700559
[TBL] [Abstract][Full Text] [Related]
7. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
Hussain I; Harrison DC; Hawkins J; Chapman T; Marshall I; Facci L; Ahmed S; Brackenborough K; Skaper SD; Mead TL; Smith BB; Giblin GM; Hall A; Gonzalez MI; Richardson JC
Neurodegener Dis; 2011; 8(1-2):15-24. PubMed ID: 20689247
[TBL] [Abstract][Full Text] [Related]
8. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.
Eriksen JL; Sagi SA; Smith TE; Weggen S; Das P; McLendon DC; Ozols VV; Jessing KW; Zavitz KH; Koo EH; Golde TE
J Clin Invest; 2003 Aug; 112(3):440-9. PubMed ID: 12897211
[TBL] [Abstract][Full Text] [Related]
9. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice.
Lanz TA; Himes CS; Pallante G; Adams L; Yamazaki S; Amore B; Merchant KM
J Pharmacol Exp Ther; 2003 Jun; 305(3):864-71. PubMed ID: 12626636
[TBL] [Abstract][Full Text] [Related]
10. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
[TBL] [Abstract][Full Text] [Related]
11. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures.
Gasparini L; Rusconi L; Xu H; del Soldato P; Ongini E
J Neurochem; 2004 Jan; 88(2):337-48. PubMed ID: 14690522
[TBL] [Abstract][Full Text] [Related]
12. Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.
Portelius E; Zhang B; Gustavsson MK; Brinkmalm G; Westman-Brinkmalm A; Zetterberg H; Lee VM; Trojanowski JQ; Blennow K
Neurodegener Dis; 2009; 6(5-6):258-62. PubMed ID: 19955704
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
Imbimbo BP; Del Giudice E; Cenacchi V; Volta R; Villetti G; Facchinetti F; Riccardi B; Puccini P; Moretto N; Grassi F; Ottonello S; Leon A
Pharmacol Res; 2007 Apr; 55(4):318-28. PubMed ID: 17292621
[TBL] [Abstract][Full Text] [Related]
14. The same gamma-secretase accounts for the multiple intramembrane cleavages of APP.
Zhao G; Tan J; Mao G; Cui MZ; Xu X
J Neurochem; 2007 Mar; 100(5):1234-46. PubMed ID: 17241131
[TBL] [Abstract][Full Text] [Related]
15. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease.
Yan Q; Zhang J; Liu H; Babu-Khan S; Vassar R; Biere AL; Citron M; Landreth G
J Neurosci; 2003 Aug; 23(20):7504-9. PubMed ID: 12930788
[TBL] [Abstract][Full Text] [Related]
17. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
Jantzen PT; Connor KE; DiCarlo G; Wenk GL; Wallace JL; Rojiani AM; Coppola D; Morgan D; Gordon MN
J Neurosci; 2002 Mar; 22(6):2246-54. PubMed ID: 11896164
[TBL] [Abstract][Full Text] [Related]
18. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.
Sivilia S; Lorenzini L; Giuliani A; Gusciglio M; Fernandez M; Baldassarro VA; Mangano C; Ferraro L; Pietrini V; Baroc MF; Viscomi AR; Ottonello S; Villetti G; Imbimbo BP; Calzà L; Giardino L
BMC Neurosci; 2013 Apr; 14():44. PubMed ID: 23560952
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
